E-Cadherin在泌尿系统恶性肿瘤中的研究进展
Advances in the Study of E-Cadherin in Urological Malignancies
DOI: 10.12677/acm.2025.1541197, PDF,   
作者: 颜肇杰：赣南医科大学第一临床医学院，江西 赣州；赣南医科大学泌尿外科研究所，江西 赣州；张国玺*：赣南医科大学第一临床医学院，江西 赣州；赣南医科大学泌尿外科研究所，江西 赣州；赣南医科大学第一附属医院泌尿外科，江西 赣州
关键词: E-Cadherin；前列腺癌；膀胱癌；肾癌；上皮间充质转化；E-Cadherin； Prostate Cancer； Bladder Cancer； Renal Cell Carcinoma； Epithelial-Mesenchymal Transition
摘要: 近年来，泌尿系统肿瘤发病率呈显著上升，如最常见的前列腺癌、膀胱癌和肾细胞癌，占据了恶性肿瘤总发病率相当大的比例。目前认为，导致泌尿系统恶性肿瘤患者死亡的主要原因是肿瘤发生远处器官转移，最终导致器官功能衰竭，转移的潜在机制仍尚未十分明确，有待进一步阐明。据了解，E-cadherin是一种钙依赖性细胞间黏附分子，在细胞黏附和维持细胞表型以及分化中起关键作用。同时，它也参与细胞的运动，在上皮间充质转化(EMT)过程中起重要作用，是EMT过程的标志，确认与肿瘤进展密切相关。E-cadherin表达的缺失能够介导肿瘤进展，引发严重不良后果。在本综述中，我们简要概述了E-cadherin的结构和功能，并系统阐述其在泌尿系统恶性肿瘤的研究进展。
Abstract: In recent years, the incidence of urological malignancies has shown a significant increase. The most common types, such as prostate cancer, bladder cancer, and renal cell carcinoma, account for a considerable proportion of the total incidence of malignant tumors. Currently, the primary cause of death in patients with urological malignancies is distant organ metastasis, which ultimately leads to organ failure. The underlying mechanisms of metastasis are still not fully understood and require further elucidation. E-cadherin is a calcium-dependent cell adhesion molecule that plays a crucial role in cell adhesion, maintaining cell phenotype and differentiation. It is also involved in cell motility and is a key factor in the epithelial-mesenchymal transition (EMT) process, which is a hallmark of tumor progression. Loss of E-cadherin expression is associated with adverse outcomes in various cancers, including urological malignancies. In this review, we briefly summarize the structure and function of E-cadherin and systematically discuss the recent advances in its role in urological malignancies.
文章引用：颜肇杰, 张国玺. E-Cadherin在泌尿系统恶性肿瘤中的研究进展[J]. 临床医学进展, 2025, 15(4): 2432-2438. https://doi.org/10.12677/acm.2025.1541197

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Gul, A. and Rini, B.I. (2019) Adjuvant Therapy in Renal Cell Carcinoma. Cancer, 125, 2935-2944. [Google Scholar] [CrossRef] [PubMed]
[3] Liu, F., Zhang, H., Xie, F., Tao, D., Xiao, X., Huang, C., et al. (2022) Correction: Hsa_circ_0001361 Promotes Bladder Cancer Invasion and Metastasis through miR-491-5p/MMP9 Axis. Oncogene, 41, 4183-4183. [Google Scholar] [CrossRef] [PubMed]
[4] Yang, L., Zou, X., Zou, J. and Zhang, G. (2021) A Review of Recent Research on the Role of MicroRNAs in Renal Cancer. Medical Science Monitor, 27, e930639. [Google Scholar] [CrossRef] [PubMed]
[5] Gillessen, S., Armstrong, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., et al. (2022) Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82, 115-141. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, G., Zhao, D., Spring, D.J. and DePinho, R.A. (2018) Genetics and Biology of Prostate Cancer. Genes & Development, 32, 1105-1140. [Google Scholar] [CrossRef] [PubMed]
[7] Yoshida-Noro, C., Suzuki, N. and Takeichi, M. (1984) Molecular Nature of the Calcium-Dependent Cell-Cell Adhesion System in Mouse Teratocarcinoma and Embryonic Cells Studied with a Monoclonal Antibody. Developmental Biology, 101, 19-27. [Google Scholar] [CrossRef] [PubMed]
[8] Loh, C., Chai, J., Tang, T., Wong, W., Sethi, G., Shanmugam, M., et al. (2019) The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells, 8, Article 1118. [Google Scholar] [CrossRef] [PubMed]
[9] Mendonsa, A.M., Na, T. and Gumbiner, B.M. (2018) E-Cadherin in Contact Inhibition and Cancer. Oncogene, 37, 4769-4780. [Google Scholar] [CrossRef] [PubMed]
[10] Navarro, P., Gómez, M., Pizarro, A., Gamallo, C., Quintanilla, M. and Cano, A. (1991) A Role for the E-Cadherin Cell-Cell Adhesion Molecule during Tumor Progression of Mouse Epidermal Carcinogenesis. The Journal of Cell Biology, 115, 517-533. [Google Scholar] [CrossRef] [PubMed]
[11] Birchmeier, W. and Behrens, J. (1994) Cadherin Expression in Carcinomas: Role in the Formation of Cell Junctions and the Prevention of Invasiveness. Biochimica et Biophysica Acta—Reviews on Cancer, 1198, 11-26. [Google Scholar] [CrossRef] [PubMed]
[12] Schneider, M.R. and Kolligs, F.T. (2014) E-Cadherin’s Role in Development, Tissue Homeostasis and Disease: Insights from Mouse Models. BioEssays, 37, 294-304. [Google Scholar] [CrossRef] [PubMed]
[13] Rosso, M., Majem, B., Devis, L., Lapyckyj, L., Besso, M.J., Llauradó, M., et al. (2017) E-Cadherin: A Determinant Molecule Associated with Ovarian Cancer Progression, Dissemination and Aggressiveness. PLOS ONE, 12, e0184439. [Google Scholar] [CrossRef] [PubMed]
[14] Hu, Q., Kuang, J., Yang, Q., Bian, X. and Yu, S. (2016) Beyond a Tumor Suppressor: Soluble E-Cadherin Promotes the Progression of Cancer. International Journal of Cancer, 138, 2804-2812. [Google Scholar] [CrossRef] [PubMed]
[15] van Roy, F. and Berx, G. (2008) The Cell-Cell Adhesion Molecule E-Cadherin. Cellular and Molecular Life Sciences, 65, 3756-3788. [Google Scholar] [CrossRef] [PubMed]
[16] Beavon, I.R.G. (2000) The E-Cadherin–catenin Complex in Tumour Metastasis. European Journal of Cancer, 36, 1607-1620. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, A., Dunn, A.R. and Weis, W.I. (2022) Mechanism of the Cadherin-Catenin F-Actin Catch Bond Interaction. E Life, 11, e80130. [Google Scholar] [CrossRef] [PubMed]
[18] Nelson, W.J. and Nusse, R. (2004) Convergence of Wnt, Ss-Catenin, and Cadherin Pathways. Science, 303, 1483-1487. [Google Scholar] [CrossRef] [PubMed]
[19] Tang, M.K.S., Yue, P.Y.K., Ip, P.P., Huang, R., Lai, H., Cheung, A.N.Y., et al. (2018) Soluble E-Cadherin Promotes Tumor Angiogenesis and Localizes to Exosome Surface. Nature Communications, 9, Article No. 2270. [Google Scholar] [CrossRef] [PubMed]
[20] De Santis, G., Miotti, S., Mazzi, M., Canevari, S. and Tomassetti, A. (2009) E-Cadherin Directly Contributes to PI3K/AKT Activation by Engaging the Pi3k-P85 Regulatory Subunit to Adherens Junctions of Ovarian Carcinoma Cells. Oncogene, 28, 1206-1217. [Google Scholar] [CrossRef] [PubMed]
[21] Grosheva, I., Shtutman, M., Elbaum, M. and Bershadsky, A.D. (2001) P120 Catenin Affects Cell Motility via Modulation of Activity of Rho-Family Gtpases: A Link between Cell-Cell Contact Formation and Regulation of Cell Locomotion. Journal of Cell Science, 114, 695-707. [Google Scholar] [CrossRef] [PubMed]
[22] Wong, S.H.M., Fang, C.M., Chuah, L., Leong, C.O. and Ngai, S.C. (2018) E-Cadherin: Its Dysregulation in Carcinogenesis and Clinical Implications. Critical Reviews in Oncology/Hematology, 121, 11-22. [Google Scholar] [CrossRef] [PubMed]
[23] López-Moncada, F., Torres, M.J., Lavanderos, B., Cerda, O., Castellón, E.A. and Contreras, H.R. (2022) SPARC Induces E-Cadherin Repression and Enhances Cell Migration through Integrin Αvβ3 and the Transcription Factor ZEB1 in Prostate Cancer Cells. International Journal of Molecular Sciences, 23, Article 5874. [Google Scholar] [CrossRef] [PubMed]
[24] Na, T., Schecterson, L., Mendonsa, A.M. and Gumbiner, B.M. (2020) The Functional Activity of E-Cadherin Controls Tumor Cell Metastasis at Multiple Steps. Proceedings of the National Academy of Sciences, 117, 5931-5937. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, G., Yang, H., Liu, T. and Lin, Y. (2014) Expression and Significance of E-Cadherin, N-Cadherin, Transforming Growth Factor-Β1 and Twist in Prostate Cancer. Asian Pacific Journal of Tropical Medicine, 7, 76-82. [Google Scholar] [CrossRef] [PubMed]
[26] Jaggi, M., Johansson, S.L., Baker, J.J., Smith, L.M., Galich, A. and Balaji, K.C. (2005) Aberrant Expression of E-Cadherin and Beta-Catenin in Human Prostate Cancer. Urologic Oncology: Seminars and Original Investigations, 23, 402-406. [Google Scholar] [CrossRef] [PubMed]
[27] Olson, A., Le, V., Aldahl, J., Yu, E., Hooker, E., He, Y., et al. (2019) The Comprehensive Role of E-Cadherin in Maintaining Prostatic Epithelial Integrity during Oncogenic Transformation and Tumor Progression. PLOS Genetics, 15, e1008451. [Google Scholar] [CrossRef] [PubMed]
[28] Syed, V., Mak, P., Du, C. and Balaji, K.C. (2007) β-Catenin Mediates Alteration in Cell Proliferation, Motility and Invasion of Prostate Cancer Cells by Differential Expression of E-Cadherin and Protein Kinase D1. Journal of Cellular Biochemistry, 104, 82-95. [Google Scholar] [CrossRef] [PubMed]
[29] Verras, M. and Sun, Z. (2006) Roles and Regulation of Wnt Signaling and β-Catenin in Prostate Cancer. Cancer Letters, 237, 22-32. [Google Scholar] [CrossRef] [PubMed]
[30] Kim, N., Koh, E., Chen, X. and Gumbiner, B.M. (2011) E-Cadherin Mediates Contact Inhibition of Proliferation through Hippo Signaling-Pathway Components. Proceedings of the National Academy of Sciences, 108, 11930-11935. [Google Scholar] [CrossRef] [PubMed]
[31] Dhar, S., Kumar, A., Gomez, C.R., Akhtar, I., Hancock, J.C., Lage, J.M., et al. (2017) MTA1-Activated Epi-MicroRNA-22 Regulates E-Cadherin and Prostate Cancer Invasiveness. FEBS Letters, 591, 924-933. [Google Scholar] [CrossRef] [PubMed]
[32] Sethi, S., Macoska, J., Chen, W., et al. (2010) Molecular Signature of Epithelial-Mesenchymal Transition (EMT) in Human Prostate Cancer Bone Metastasis. American Journal of Translational Research, 3, 90-99.
[33] Kandouz, M., Alachkar, A., Zhang, L., Dekhil, H., Chehna, F., Yasmeen, A., et al. (2010) Teucrium Polium Plant Extract Inhibits Cell Invasion and Motility of Human Prostate Cancer Cells via the Restoration of the E-Cadherin/Catenin Complex. Journal of Ethnopharmacology, 129, 410-415. [Google Scholar] [CrossRef] [PubMed]
[34] Bonaldi, C.M., Azzalis, L.A., Junqueira, V.B.C., de Oliveira, C.G.B., Boas, V.A.V., Gáscon, T.M., et al. (2015) Plasma Levels of E-Cadherin and MMP-13 in Prostate Cancer Patients: Correlation with PSA, Testosterone and Pathological Parameters. Tumori Journal, 101, 185-188. [Google Scholar] [CrossRef] [PubMed]
[35] Wang, X., Dong, B., Zhang, K., Ji, Z., Cheng, C., Zhao, H., et al. (2018) E-Cadherin Bridges Cell Polarity and Spindle Orientation to Ensure Prostate Epithelial Integrity and Prevent Carcinogenesis in Vivo. PLOS Genetics, 14, e1007609. [Google Scholar] [CrossRef] [PubMed]
[36] Zhao, J., Dong, D., Sun, L., Zhang, G. and Sun, L. (2014) Prognostic Significance of the Epithelial-to-Mesenchymal Transition Markers E-Cadherin, Vimentin and Twist in Bladder Cancer. International Brazilian Journal of Urology, 40, 179-189. [Google Scholar] [CrossRef] [PubMed]
[37] Breyer, J., Gierth, M., Shalekenov, S., Aziz, A., Schäfer, J., Burger, M., et al. (2015) Epithelial-Mesenchymal Transformation Markers E-Cadherin and Survivin Predict Progression of Stage PTA Urothelial Bladder Carcinoma. World Journal of Urology, 34, 709-716. [Google Scholar] [CrossRef] [PubMed]
[38] Shash, L.S., Ibrahim, R.A. and Elgohary, S.A. (2021) E-Cadherin and N-Cadherin Immunohistochemical Expression in Proliferating Urothelial Lesions: Potential Novel Cancer Predictive EMT Profiles. Applied Immunohistochemistry & Molecular Morphology, 29, 657-666. [Google Scholar] [CrossRef] [PubMed]
[39] Otto, W., Breyer, J., Herdegen, S., Eder, F., Bertz, S., May, M., et al. (2016) WHO 1973 Grade 3 and Infiltrative Growth Pattern Proved, Aberrant E-Cadherin Expression Tends to Be of Predictive Value for Progression in a Series of Stage T1 High-Grade Bladder Cancer after Organ-Sparing Approach. International Urology and Nephrology, 49, 431-437. [Google Scholar] [CrossRef] [PubMed]
[40] Fan, T., Xue, L., Dong, B., He, H., Zhang, W., Hao, L., et al. (2022) CDH1 Overexpression Predicts Bladder Cancer from Early Stage and Inversely Correlates with Immune Infiltration. BMC Urology, 22, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
[41] Jing, W., Cao, Y., Wang, H., et al. (2023) E-Cadherin and FGFR3 Are Risk Factors Determining Prognosis of Patients with Bladder Urothelial Carcinoma. American Journal of Translational Research, 15, 1510-1516.
[42] Yang, T., Fan, J., Liang, H., He, D., Zeng, X., Fan, J., et al. (2020) Reduced E-Cadherin Expression as a Prognostic Factor in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Progrès en Urologie, 30, 66-74. [Google Scholar] [CrossRef] [PubMed]
[43] Muramaki, M., Miyake, H., Terakawa, T., Kumano, M., Sakai, I. and Fujisawa, M. (2012) Expression Profile of E-Cadherin and N-Cadherin in Non-Muscle-Invasive Bladder Cancer as a Novel Predictor of Intravesical Recurrence Following Transurethral Resection. Urologic Oncology: Seminars and Original Investigations, 30, 161-166. [Google Scholar] [CrossRef] [PubMed]
[44] Balci, M.G. and Tayfur, M. (2018) Loss of E-Cadherin Expression in Recurrent Non-Invasive Urothelial Carcinoma of the Bladder. International Journal of Clinical and Experimental Pathology, 11, 4163-4168.
[45] Borzym-Kluczyk, M., Radziejewska, I., Cechowska-Pasko, M. and Darewicz, B. (2017) Reduced Expression of E-Cadherin and Increased Sialylation Level in Clear Cell Renal Cell Carcinoma. Acta Biochimica Polonica, 64, 465-470. [Google Scholar] [CrossRef] [PubMed]
[46] Gao, Y., Yan, Y., Guo, J., Zhang, Q., Bi, D., Wang, F., et al. (2019) HNF‑4α Downregulation Promotes Tumor Migration and Invasion by Regulating E‑Cadherin in Renal Cell Carcinoma. Oncology Reports, 42, 1066-1074. [Google Scholar] [CrossRef] [PubMed]
[47] Bhat, N.S., Colden, M., Dar, A.A., Saini, S., Arora, P., Shahryari, V., et al. (2017) MicroRNA-720 Regulates E-Cadherin-αe-Catenin Complex and Promotes Renal Cell Carcinoma. Molecular Cancer Therapeutics, 16, 2840-2848. [Google Scholar] [CrossRef] [PubMed]

为你推荐